As a result of Nanologica’s product in preparative chromatography, NLAB Saga®, reaching internal quality requirements, silica is now delivered to a customer in Latin America for production of diabetes drugs.
The customer is a latin-american pharmaceutical manufacturer that manufactures, among other things, insulin and insulin analogues. This delivery refers to silica for the production of insulin. The delivery is made against a recent order with an order value of about TSEK 300.
”We have for some time collaborated with this customer on the purification of one of their diabetes drugs where we at the end of last year conducted method development, after which they initiated evaluation of our silica. Now that we have a product from our large-scale plant that we are satisfied with, we supply silica so that they can include it in their production”, Katarina Alenäs, Senior Vice President Chromatography at Nanologica comments.
Several customers have successfully evaluated Nanologica’s silica for preparative chromatography, NLAB Saga®, in different stages. Last year, the company took multiple orders for large-scale evaluation.
”The orders we have taken so far consist of several different product types at different volumes. The first delivery that is now dispatched is one type of product, but we will gradually deliver other product types in demanded volumes. I remain very optimistic about our opportunities to gradually establish ourselves as a supplier of high-quality silica for purification of peptides and it is very gratifying that our silica is included in a customer’s production for the first time”, Nanologica’s CEO Andreas Bhagwani continues.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: firstname.lastname@example.org
About Nanologica AB (publ)
Nanologica manufactures and sells nanoporous silica particles for applications within life science. A proprietary production method enables the company to create world-class products by precisely controlling the shape, size, porosity, and surface properties of silica particles. The company provides high-quality silica products used in the purification of peptide drugs. These products can contribute to lower costs and higher production for pharmaceutical manufacturers, which increases the availability of cost-effective medicines and gives more people around the world access to vital treatment for diabetes and obesity. Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) has been listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.